Heparin, commonly known as unfractionated heparin (UFH), is a naturally occurring glycosaminoglycan. It is used in medicine as an anticoagulant (blood thinner). It is very beneficial in the treatment of heart attacks and angina pectoris. It's injected either into a vein or under the skin. Acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during heart surgery, are all treated with it. It can also be used to provide major orthopedic surgeries like hip and knee replacements. The COVID-19 pandemic has caused chaos on health-care workflows all around the world. A huge number of individuals are suffering from coronavirus, which is associated to respiratory disorders, during the COVID-19 pandemic. As a result, the demand for heparin has risen, as it aids in the management of pulmonary inflation and the thinning of the blood of people at risk of a blood clot.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
The rising global prevalence of cardiovascular disorders, such as heart attacks and strokes, will provide market possibilities. According to the American Heart Association's (AHA) Heart Disease and Stroke Statistics, atrial fibrillation affected 5.3 million Americans in 2019. The rising patient demand for heparin might have a significant influence on the market.
In December 2020, Valeo Pharma Inc. gained approval from Health Canada for its low molecular weight heparin 'Redesca and Redesca HP'.
In May 2020, The University of Manitoba launched a research research to see if heparin, a blood-thinning medicine, can be used to treat COVID-19 patients. The clinical experiment took place in 35 different locations across Canada, the United States, Mexico, and Brazil.
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Select License Type
US : +1 (716) 218-3733
UK : +44 (208) 1235555
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT